
Ventas (VTR) Stock Forecast & Price Target
Ventas (VTR) Analyst Ratings
Bulls say
Ventas's diversified healthcare portfolio, comprising nearly 1,400 properties across various sectors, places the company in a strong position to capture growth as EBITDAR is projected to potentially double from approximately $50 million to $100 million over time. The estimated in-place net asset value (NAV) is expected to rise significantly from $55.85 per share at year-end 2025 to $63.15 per share by year-end 2026, highlighting an optimistic growth outlook fueled by robust trends in seniors housing and effective capital utilization. Additionally, the firm's strategic focus on expanding its investment pipeline and leveraging its relationships to secure new deals indicates a strong foundation for high single-digit annual growth driven by healthy demand and improving occupancy rates.
Bears say
Ventas faces a negative outlook primarily due to worsened cost of capital which may prevent the company from pursuing new investment opportunities, leading to a downward revision of its Adjusted Funds From Operations (AFFO) estimates. Additionally, the growth outlook for senior housing appears muted, with occupancy and revenue per occupied room (REVPOR) growth being offset by rising expenses, thereby limiting overall financial improvement. Furthermore, the potential for reductions in federal healthcare budgets, such as the National Institutes of Health (NIH) and Medicare/Medicaid reimbursements, could adversely affect rent coverage ratios and overall financial stability.
This aggregate rating is based on analysts' research of Ventas and is not a guaranteed prediction by Public.com or investment advice.
Ventas (VTR) Analyst Forecast & Price Prediction
Start investing in Ventas (VTR)
Order type
Buy in
Order amount
Est. shares
0 shares